Search | Clinical Trials Finder

Conditions: Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute
Interventions: Not listed
Lead sponsor: University of Rochester; Other
Eligibility: Up to 50 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Rochester, New York

Conditions: High Risk Pregnancy, Congenital Heart Disease, Fetal Hydrops, Twin Monochorionic Monoamniotic Placenta, Gastroschisis, Fetal Demise, Stillbirth, Fetal Arrhythmia, Long QT Syndrome, Intrauterine Fetal Death, Sudden Infant Death, Pregnancy Loss, Twin Twin Transfusion Syndrome, Birth Defect, Fetal Cardiac Anomaly, Fetal Cardiac Disorder, Fetal Death, Brugada Syndrome, Fetal Tachycardia
Interventions: Fetal Magnetocardiogram and Neonatal Electrocardiogram, Substudy only: Maternal/Infant Pharmacogenomic assessment postnatally; Diagnostic Test · Genetic
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Myelodysplastic Syndrome (MDS)
Interventions: ezatiostat hydrochloride (Telintra®); Drug
Lead sponsor: Telik; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 5
States / cities: Maywood, Illinois • Springfield, Illinois • Bethesda, Maryland + 2 more

Conditions: Pancreaticoduodenectomy, Pancreatectomy, Esophagectomy, Gastrectomy, Hepatectomy
Interventions: Not listed
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 2
States / cities: Louisville, Kentucky

Conditions: Preterm Birth
Interventions: Deferred cord clamping; Procedure
Lead sponsor: University of Sydney; Other
Eligibility: Female only
Enrollment: 1,637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 2
States / cities: Houston, Texas • Burlington, Vermont

Conditions: Twin to Twin Transfusion Syndrome
Interventions: Curved KARL STORZ fetoscope, Conventional Scopes; Device
Lead sponsor: Jimmy Espinoza; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Erythrocyte Transfusion, Beta-Thalassemia
Interventions: Luspatercept, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 6
States / cities: Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more

Conditions: Anemia of Prematurity, Necrotizing Enterocolitis
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: Up to 12 Weeks
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 3
States / cities: Murray, Utah • Salt Lake City, Utah

Conditions: Sickle Cell Disease
Interventions: Transfusion; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia • Chapel Hill, North Carolina • Milwaukee, Wisconsin

Conditions: Traumatic Intracranial Hemorrhage
Interventions: Repeat Thromboelastography with Platelet Mapping; Diagnostic Test
Lead sponsor: Lancaster General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Epithelial Ovarian Cancer, Anemia, Iron Deficiency Anemia
Interventions: Iron Sucrose; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Blood Transfusion
Interventions: Label applied to blood bag; Procedure
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 6
States / cities: Los Angeles, California • Boston, Massachusetts • Lebanon, New Hampshire + 2 more

Conditions: Anemia, Sickle Cell, Transfusion Hemosiderosis
Interventions: deferasirox; Drug
Lead sponsor: Children's Hospital Los Angeles; Other
Eligibility: 14 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-alcoholic Steatohepatitis, Chronic Liver Disease, HCV, NASH - Nonalcoholic Steatohepatitis, HIV Infection, Thrombocytopenia, Hepatitis C Virus, HBV, Human Immunodeficiency Virus, Liver Diseases, Hepatitis B Virus
Interventions: Eltrombopag, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 33
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 28 more

Conditions: Paroxysmal Hemoglobinuria, Nocturnal
Interventions: eculizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 14
States / cities: Stanford, California • Hartford, Connecticut • Weston, Florida + 10 more

Conditions: Hemochromatosis, Cerebrovascular Accident, Anemia, Sickle Cell, Hematologic Diseases
Interventions: Red Cell Transfusions, Iron Chelation, Hydroxyurea, Phlebotomy; Procedure · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years to 18 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 28
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Jacksonville, Florida + 23 more

Conditions: Transfusion-related Acute Lung Injury, Chronic Liver Disease, Gastrointestinal Bleeding
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Hemoglobin, Cerebral Oxygenation, Congenital Heart Disease
Interventions: Noninvasive hemoglobin monitoring; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 0 Days to 21 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Blood Loss, Surgical
Interventions: Trasylol (Aprotinin, BAYA0128), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 27
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 24 more

Conditions: Subarachnoid Hemorrhage, Aneurysmal
Interventions: Liberal RBC Transfusion Strategy, Restrictive RBC Transfusion Strategy; Other
Lead sponsor: Ottawa Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 3
States / cities: Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois

Conditions: Sickle Cell Disease, Thalassemia
Interventions: Etavopivat tablets; Drug
Lead sponsor: Forma Therapeutics, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 14
States / cities: Cerritos, California • Los Angeles, California • Oakland, California + 9 more

Conditions: Blood Loss, Anatomic Total Shoulder Arthroplasty, Reverse Total Shoulder Arthroplasty, Transfusion, Tranexamic Acid
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: Not listed
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Iron Overload, Beta-Thalassemia
Interventions: SP-420; Drug
Lead sponsor: Sideris Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania

Conditions: Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Interventions: REGN7999, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia

Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise

Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome

Intraoperative Cell Saver Autotransfusion Use for Major Surgical Oncology Operations.

The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures?

The Efficacy of the KARL STORZ Curved Fetoscope and Straight Fetoscope for Laser Photocoagulation of Placental Anastomoses

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia

Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates

Age of Blood in Sickle Cell Transfusion

Platelet Transfusion and Repeat TEG-PM in Patients With Severe TBI on Antiplatelet Therapy (Repeat TEG-PM)

Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

Transfusion Medicine - Prevention of Bedside Errors

Clinical Importance of Treating Iron Overload in Sickle Cell Disease

Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures

Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)

Stroke With Transfusions Changing to Hydroxyurea

Predicting Lung Injury From Transfusion in Patients With Liver Disease

Observational Data Collection for Blood Hemoglobin Algorithm Validation in Pediatrics

Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement

SAHaRA: A Randomized Controlled Trial

A Study of Etavopivat in Patients With Thalassemia or Sickle Cell Disease

Investigation of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty

Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body